Antibody Information

General Information of This Antibody
Antibody ID
ANI0MDDEU
Antibody Name
Vadastuximab
Organization
Seagen Inc.
Indication
Acute myeloid leukemia; Acute promyelocytic leukemia; Myelodysplastic syndromes
Synonyms
h2H12ec
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Chimeric IgG1-kappa
Antigen Name
Myeloid cell surface antigen CD33 (CD33)
  Antigen Info 
ChEMBI ID
CHEMBL3990024
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence
XVQLVQSGAEVKKPGASVKVSCKASGYTFTNYDINWVRQAPGQGLEWIGWIYPGDGSTKY
NEKFKAKATLTADTSTSTAYMELRSLRSDDTAVYYCASGYEDAMDYWGQGTTVTVSSAST
KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPCV
FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK
NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG
NVFSCSVMHEALHNHYTQKSLSLSPGK
    Click to Show/Hide
Heavy Chain Varible Domain
QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYDINWVRQAPGQGLEWIGWIYPGDGSTKY
NEKFKAKATLTADTSTSTAYMELRSLRSDDTAVYYCASGYEDAMDYWGQGTTVTVSS
    Click to Show/Hide
Heavy Chain Constant Domain 1
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
    Click to Show/Hide
Heavy Chain Constant Domain 2
APELLGGPCVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
    Click to Show/Hide
Heavy Chain Constant Domain 3
GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    Click to Show/Hide
Heavy Chain Hinge Region
EPKSCDKTHTCPPCP
    Click to Show/Hide
Heavy Chain CDR 1
GYTFTNYD
    Click to Show/Hide
Heavy Chain CDR 2
IYPGDGST
    Click to Show/Hide
Heavy Chain CDR 3
ASGYEDAMDY
    Click to Show/Hide
Light Chain Sequence
DIQMTQSPSSLSASVGDRVTINCKASQDINSYLSWFQQKPGKAPKTLIYRANRLVDGVPS
RFSGSGSGQDYTLTISSLQPEDFATYYCLQYDEFPLTFGGGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain Varible Domain
DIQMTQSPSSLSASVGDRVTINCKASQDINSYLSWFQQKPGKAPKTLIYRANRLVDGVPS
RFSGSGSGQDYTLTISSLQPEDFATYYCLQYDEFPLTFGGGTKVEIK
    Click to Show/Hide
Light Chain Constant Domain
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain CDR 1
QDINSY
    Click to Show/Hide
Light Chain CDR 2
RAN
    Click to Show/Hide
Light Chain CDR 3
LQYDEFPLT
    Click to Show/Hide
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Vadastuximab talirine [Terminated in phase 3]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 7 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Incomplete Count Recovery (CRi)
26.00% (Placebo + HMA)
Patients Enrolled
Older patients with newly diagnosed acute myeloid leukemia (AML).
Administration Dosage
33A, iv, 10 mcg/kg, every 4 weeks plus azacitidine 75 mg/m2, SC or IV x 7 days, every 4 weeks or decitabine 20 mg/m2, iv x 5 days, every 4 weeks; placebo plus plus azacitidine 75 mg/m2, SC or IV x 7 days, every 4 weeks or decitabine 20 mg/m2, iv x 5 days, every 4 weeks.
Related Clinical Trial
NCT Number NCT02326584  Clinical Status Phase 1
Clinical Description
A phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia.
Experiment 2 Reporting the Activity Date of This ADC [2]
Efficacy Data Complete Remission (CR)
66.70% (Pre-allo Before Stem Cell Transplant)
Patients Enrolled
Patients With Relapsed or Refractory AmL.
Administration Dosage
Post-allo after stem cell transplant in Day 1 of each cycle; Pre-allo in Day 1 of each cycle plus melphalan 30 mg/m2/day iv and fludarabine 140 mg/m2 iv before stem cell transplant.
Related Clinical Trial
NCT Number NCT02785900  Clinical Status Phase 3
Clinical Description
A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML).
Experiment 3 Reporting the Activity Date of This ADC [3]
Efficacy Data Complete Remission (CR)
11.00% (all treated, dose escalation/expansion 40 ug/kg)
12.00% (efficacy evaluable, dose escalation/expansion 40 ug/kg)
22.00% (all treated
treatment naive 40 ug/kg)
23.00% (efficacy evaluable, treatment naive 40 ug/kg)
Patients Enrolled
CD33-positive AmL (any level of CD33 expression as detected by local flow cytometric assessment) and had either newly diagnosed AmL (declining intensive induction/consolidation chemotherapy) or AmL relapsed after a minimum remission duration of 12 weeks after intensive induction/consolidation.
Administration Dosage
Slow IV push on day 1 (5-60 ug/kg) or on days 1 and 4 (20 ug/kg) of 21-day cycles.
Related Clinical Trial
NCT Number NCT01902329  Clinical Status Phase 1
Clinical Description
A phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia.
Primary Endpoint
The recommended monotherapy dose is 4.00 mg/kg.
Other Endpoint
The complete remission rate (CRc) among the 69 patients in the dose-finding cohorts, was 19.00% (6.00% CR + 13.00% CRi, 95% confidence interval [CI], 10.40-30.10).
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Complete Remission (CR)
30.00% (33A + HMA)
26.00% (Placebo + HMA)
Patients Enrolled
Older patients with newly diagnosed acute myeloid leukemia (AML).
Administration Dosage
33A, iv, 10 mcg/kg, every 4 weeks plus azacitidine 75 mg/m2, SC or IV x 7 days, every 4 weeks or decitabine 20 mg/m2, iv x 5 days, every 4 weeks; placebo plus plus azacitidine 75 mg/m2, SC or IV x 7 days, every 4 weeks or decitabine 20 mg/m2, iv x 5 days, every 4 weeks.
Related Clinical Trial
NCT Number NCT02326584  Clinical Status Phase 1
Clinical Description
A phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia.
Experiment 5 Reporting the Activity Date of This ADC [4]
Efficacy Data Complete Remission (CR)
43.00% (all treated)
42.00% (secondary AmL)
34.00% (75 y old)
80.00% (FLT3/ITD+)
50.00% (MRC adv)
39.00% (Und. Myelo)
Patients Enrolled
New diagnosis of CD33-expressing AmL, they could not have received prior therapy with HMAs; however, prior low-intensity treatment, such as hydroxyurea for cytoreduction or other low-intensity therapies for preceding myelodysplastic syndrome (MDS), an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, with adequate baseline renal, hepatic, and pulmonary function.

   Click to Show/Hide
Administration Dosage
Azacitidine (75 mg/m2 subcutaneous/intravenous 7 days) or decitabine (20 mg/m2 intravenous 5 days) was administered per institutional standard. On the final day of HMA administration (day 7 of azacitidine treatment and day 5 of decitabine treatment), vadastuximab talirine (10 ug/kg) was administered via slow intravenous push (1-2 mL/min), after infusion of the HMA, as 28-day cycles for up to 4 cycles of treatment.

   Click to Show/Hide
Related Clinical Trial
NCT Number NCT01902329  Clinical Status Phase 1
Clinical Description
A phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia.
Primary Endpoint
The 30- and 60-day mortality rates were 2% and 8%, respectively. No DLTs or infusion-related reactions were observed in the combination cohort of this study.
Other Endpoint
CR and CRi, was 70.00% (43% CR + 26% CRi, 95% CI, 55.70-81.70). Median RFS was 7.70 months (95% CI, 4.90-15.40) with 11.30 months (95% CI, 8.80-13.20) median OS.
Experiment 6 Reporting the Activity Date of This ADC [5]
Patients Enrolled
Patients with operable HER2-positive primary breast cancer.
Administration Dosage
Anthracycline then Trastuzumab Emtansine and Pertuzumab ; Anthracycline then Trastuzumab, Pertuzumab, and Taxane.
Related Clinical Trial
NCT Number NCT02614560  Clinical Status Phase 1/2
Clinical Description
A phase 1/2 study of vadastuximab talirine administered in sequence with allogeneic hematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukemia (AML).
Experiment 7 Reporting the Activity Date of This ADC [6]
Patients Enrolled
Patients With acute myeloid leukemia (AML).
Administration Dosage
SGN-CD33A iv in Day 1 or Days 1 and 4 of each cycle; High dose cytarabine + SGN-CD33A (28-day cycles); Standard dose cytarabine and daunorubicin + SGN-CD33A; standard dose cytarabine and daunorubicin + SGN-CD33A and High dose cytarabine + SGN-CD33A.
Related Clinical Trial
NCT Number NCT01902329  Clinical Status Phase 1
Clinical Description
A phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia.
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 8 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [7]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 0.00% (Day 36) High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 100mcg/kg.
In Vitro Model Erythroleukemia HEL 92.1.7 cells (Multidrug resistance) CVCL_2481
Experiment 2 Reporting the Activity Date of This ADC [7]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 29.44% (Day 30) High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 30mcg/kg.
In Vitro Model Adult acute myeloid leukemia HL-60 cells CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC [7]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 47.77% (Day 36) High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 300mcg/kg.
In Vitro Model Erythroleukemia HEL 92.1.7 cells (Multidrug resistance) CVCL_2481
Experiment 4 Reporting the Activity Date of This ADC [7]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 78.95% (Day 38) Negative CD33 expression (CD33-)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 100mcg/kg.
In Vitro Model Anaplastic thyroid cancer TF1-alpha cells (Multidrug resistance) Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC [7]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 98.41% (Day 36) High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 1000mcg/kg.
In Vitro Model Erythroleukemia HEL 92.1.7 cells (Multidrug resistance) CVCL_2481
Experiment 6 Reporting the Activity Date of This ADC [7]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 98.53% (Day 38) Negative CD33 expression (CD33-)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 300mcg/kg.
In Vitro Model Anaplastic thyroid cancer TF1-alpha cells (Multidrug resistance) Homo sapiens
Experiment 7 Reporting the Activity Date of This ADC [7]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 99.99% (Day 30) High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 100mcg/kg.
In Vitro Model Adult acute myeloid leukemia HL-60 cells CVCL_0002
Experiment 8 Reporting the Activity Date of This ADC [7]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 99.99% (Day 40) Negative CD33 expression (CD33-)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 300mcg/kg.
In Vitro Model Anaplastic thyroid cancer TF1-alpha cells (Multidrug resistance) Homo sapiens
Revealed Based on the Cell Line Data
Click To Hide/Show 33 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.10 ng/mL
Moderate CD33 expression (CD33++; CD33 MFI=3,919)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model Acute myeloid leukemia Acute myeloid leukemia cells #SG019 Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.10 ng/mL
Moderate CD33 expression (CD33++; 6,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model Childhood acute monocytic leukemia MV4-11 cells CVCL_0064
Experiment 3 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.20 ng/mL
High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model Acute myeloid leukemia Acute myeloid leukemia cells #SG022 Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.20 ng/mL
Moderate CD33 expression (CD33++; CD33 MFI=1,355)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model Acute myeloid leukemia Acute myeloid leukemia cells #SG014 Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.20 ng/mL
High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model Acute myeloid leukemia Acute myeloid leukemia cells #SG023 Homo sapiens
Experiment 6 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.20 ng/mL
High CD33 expression (CD33+++; CD33 MFI=10,762)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model Acute myeloid leukemia Acute myeloid leukemia cells #SG018 Homo sapiens
Experiment 7 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.20 ng/mL
High CD33 expression (CD33+++; CD33 MFI=11,850)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model Acute myeloid leukemia Acute myeloid leukemia cells #SG015 Homo sapiens
Experiment 8 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.40 ng/mL
Low CD33 expression (CD33+; CD33 MFI=107)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model Acute myeloid leukemia Acute myeloid leukemia cells #SG003 Homo sapiens
Experiment 9 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.90 ng/mL
Moderate CD33 expression (CD33++; CD33 MFI=5,817)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model Acute myeloid leukemia Acute myeloid leukemia cells #SG002 Homo sapiens
Experiment 10 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.00 ng/mL
High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model Adult acute myeloid leukemia HL-60 cells CVCL_0002
Experiment 11 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
3.00 ng/mL
High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model Adult acute myeloid leukemia KG-1 cells CVCL_0374
Experiment 12 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
5.00 ng/mL
Negative CD33 expression (CD33-; CD33 MFI=20)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model Acute myeloid leukemia Acute myeloid leukemia cells #SG017 Homo sapiens
Experiment 13 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
6.00 ng/mL
Negative CD33 expression (CD33-; CD33 MFI=49)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model Acute myeloid leukemia Acute myeloid leukemia cells #SG001 Homo sapiens
Experiment 14 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
6.00 ng/mL
High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model Acute myeloid leukemia SH-1 cells CVCL_2191
Experiment 15 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
7.00 ng/mL
High CD33 expression (CD33+++; CD33 MFI=23,223)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model Erythroleukemia HEL 92.1.7 cells CVCL_2481
Experiment 16 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
7.00 ng/mL
High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model Childhood acute monocytic leukemia THP-1 cells CVCL_0006
Experiment 17 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 7.50 ng/mL High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model Acute myeloid leukemia SIG-M5 cells CVCL_1694
Experiment 18 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
11.00 ng/mL
Moderate CD33 expression (CD33++; CD33 MFI=1,035)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model Acute myeloid leukemia Acute myeloid leukemia cells #SG008 Homo sapiens
Experiment 19 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
11.00 ng/mL
Low CD33 expression (CD33+; CD33 MFI=216)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model Acute myeloid leukemia Acute myeloid leukemia cells #SG013 Homo sapiens
Experiment 20 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
22.00 ng/mL
High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model Adult acute monocytic leukemia U-937 cells CVCL_0007
Experiment 21 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
23.00 ng/mL
Low CD33 expression (CD33+; CD33 MFI=299)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model Acute myeloid leukemia Acute myeloid leukemia cells #SG010 Homo sapiens
Experiment 22 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
26.00 ng/mL
High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model Acute myeloid leukemia HNT-34 cells CVCL_2071
Experiment 23 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
32.00 ng/mL
Moderate CD33 expression (CD33++; CD33 MFI=1,184)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model Acute myeloid leukemia Acute myeloid leukemia cells #SG004 Homo sapiens
Experiment 24 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
33.00 ng/mL
Moderate CD33 expression (CD33++; CD33 MFI=6,598)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model Acute myeloid leukemia Acute myeloid leukemia cells #SG011 Homo sapiens
Experiment 25 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
49.00 ng/mL
Moderate CD33 expression (CD33++; CD33 MFI=2,278)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model Anaplastic thyroid cancer TF1-alpha cells (Multidrug resistance) Homo sapiens
Experiment 26 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
61.00 ng/mL
Moderate CD33 expression (CD33++; 7,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model Esophageal squamous cell carcinoma TF-1 cells CVCL_1759
Experiment 27 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
68.00 ng/mL
High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model Adult acute myeloid leukemia SH-2 cells CVCL_2190
Experiment 28 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 110.00 ng/mL Negative CD33 expression (CD33-; CD33 MFI=0)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model Acute myeloid leukemia Acute myeloid leukemia cells #SG009 Homo sapiens
Experiment 29 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 110.00 ng/mL High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model Acute myeloid leukemia Acute myeloid leukemia cells #SG020 Homo sapiens
Experiment 30 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 110.00 ng/mL Low CD33 expression (CD33+; CD33 MFI=353)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model Acute myeloid leukemia Acute myeloid leukemia cells #SG012 Homo sapiens
Experiment 31 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 1000.00 ng/mL High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 32 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 1000.00 ng/mL Low CD33 expression (CD33+; CD33 MFI=318)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model Ovarian clear cell adenocarcinoma ES-2 cells CVCL_3509
Experiment 33 Reporting the Activity Date of This ADC [7]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 5000.00 ng/mL High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model Ovarian serous cystadenocarcinoma SK-OV-3 cells CVCL_0532
References
Ref 1 A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia, NCT02326584
Ref 2 A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML), NCT02785900
Ref 3 A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 2018 Jan 25;131(4):387-396.
Ref 4 A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood. 2018 Sep 13;132(11):1125-1133.
Ref 5 A Phase 1/2 Study of Vadastuximab Talirine Administered in Sequence With Allogeneic Hematopoietic Stem Cell Transplant in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML), NCT02614560
Ref 6 A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia, NCT01902329
Ref 7 SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013 Aug 22;122(8):1455-63.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.